about
Random Whole Body Vibration over 5 Weeks Leads to Effects Similar to Placebo: A Controlled Study in Parkinson's Disease.Cerebrotendinous xanthomatosis patients with and without parkinsonism: clinical characteristics and neuroimaging findings.Mitochondrial abnormalities in the putamen in Parkinson's disease dyskinesiaMotor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations.Tonic dopaminergic stimulation impairs associative learning in healthy subjects.Optimising levodopa therapy for the management of Parkinson's disease.Current approaches to the treatment of Parkinson's diseaseLevodopa unresponsive symptoms in Parkinson disease.Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet(®)), sustained-release carbidopa-levodopa (Sinemet(®) CR), and carbidopa-levodopa-enLevodopa delivery systems: advancements in delivery of the gold standard.Levodopa in Parkinson's disease: from the past to the future.How should we treat a patient with early Parkinson's disease?Design of an interpolyelectrolyte gastroretentive matrix for the site-specific zero-order delivery of levodopa in Parkinson's disease.Functional Status of Elderly Nursing Home Residents With Parkinson's Disease.Effects of GABAa receptor antagonists on motor behavior in pharmacological Parkinson's disease model in mice.'Diphasic' levodopa-induced chorea in multiple system atrophy.Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia.Isolation and characterization of mesenchymal stem cells derived from bone marrow of patients with Parkinson's disease.Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease.[Olanzapine use in cancer patients for refractory vomiting].Chlorotoxin-modified stealth liposomes encapsulating levodopa for the targeting delivery against Parkinson's disease in the MPTP-induced mice model.Unpredictable rotational responses to L-dopa in the rat model of Parkinson's disease: the role of L-dopa pharmacokinetics and striatal dopamine depletion.Effects of random whole-body vibration on postural control in Parkinson's disease.Neuroprotective Role of Phytochemicals
P2860
Q30426803-31AC76FF-F38D-41DC-BBFF-8C6FC4C20171Q33527058-160A1BA8-7105-4946-9BB5-3C9A44C5B0F9Q34203904-9D31F951-D53F-4648-A514-15E0DFECEB12Q34410406-8F758896-634C-4A8F-8410-7E5081F32B94Q34553049-896C946F-80C3-4B87-955F-3FE00CF4DA03Q36285098-722CB3DA-220F-4ED2-879D-9524355BD3FBQ36876438-9FE5F323-E35C-4A14-A335-6EBAC2B79A10Q37264473-2FC859D0-4BF7-4E33-9C33-78E910F83872Q37275476-64FCEB35-D039-42B3-8760-022C421D93E3Q37679951-99437AA1-2CEC-4E65-AE36-3EC8B295DBE1Q37693934-8C59FE24-3AF6-4466-9FC1-25C684F18A29Q37775098-3E7CD9F0-DFC4-4E2E-8F4D-8BA194609772Q39300437-797B71AD-5153-4B74-86D7-7C0FEEC8A941Q39712008-3F8F5744-91BF-4DC5-9632-C467BF112D4FQ41928667-0B032E39-BBEC-49B9-B6AA-FF9EB2896972Q43188555-9092EEBE-67D4-4B5E-9627-8B10F4EE6B63Q44383212-72DA9962-AAD5-4F59-8B10-4AF86BBF4C74Q45876693-C7192D6C-BEE4-47FD-AC26-A0DCD84A4493Q45985296-4119B3FE-0A90-4CF5-BBAD-C209A5243ED3Q46986949-F1F96E2F-97ED-46B6-880B-A72953D64261Q48794611-C35C67CB-ED73-47A6-AEB7-C52D50A42B31Q48945974-3CA1693D-4152-4513-A028-92B8873A69D7Q51293844-A29C69E6-F8C4-43D2-BAB3-E2A793EB327BQ58692870-9DB978BE-976B-469A-AD57-A52D61D0B028
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Levodopa strengths and weaknesses.
@ast
Levodopa strengths and weaknesses.
@en
Levodopa strengths and weaknesses.
@nl
type
label
Levodopa strengths and weaknesses.
@ast
Levodopa strengths and weaknesses.
@en
Levodopa strengths and weaknesses.
@nl
prefLabel
Levodopa strengths and weaknesses.
@ast
Levodopa strengths and weaknesses.
@en
Levodopa strengths and weaknesses.
@nl
P1433
P1476
Levodopa strengths and weaknesses.
@en
P304
P356
10.1212/WNL.58.SUPPL_1.S19
P407
P433
P577
2002-02-01T00:00:00Z